### Multiple Myeloma Care Translating Evolving Practices to

Oncology Nurses in Community Settings





### Faculty

Patricia Mangan, MSN, CRNP Nurse Practitioner, (Hematology/Oncology) Abramson Cancer Center University of Pennsylvania Philadelphia, PA



### Faculty Disclosure

Patricia Mangan, MSN, CRNP discloses the following relevant financial information with ineligible companies:

• Speaker's Bureau: BMS, Janssen, Karyopharm



### Planner Disclosures

#### Academy Staff

John JD Juchniewicz, MCIS, CHCP, FACEHP, Wendy Gloffke, PhD and Paul Miniter, MS – No relevant financial relationships with any ineligible companies.

#### **Clinical Reviewer**

Oxana Megherea, PharmD, BCOP

- Dr. Megherea has no relevant financial relationships with any ineligible companies.



### Commercial Support Disclosure

This activity is supported through an educational grant from Sanofi, Legend Biotech, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.



### Off-Label Usage

This presentation includes mention of medications that are not currently indicated in relapsed/refractory multiple myeloma (RRMM).



### Objectives

- 1. Review evolving treatment options in RRMM and clinical implications
- 2. Examine how academic and tertiary care centers have integrated new treatments into practice in the setting of RRMM
- 3. Identify the most common and the unique chronic adverse events associated with long-term treatment of multiple myeloma
- 4. Describe the core principles surrounding mitigating and managing chronic adverse events in patients being treated in the RRMM setting
- 5. Outline the expanding roles of nurses, advanced practice providers (APPS), and nurse navigators when patients are treated with newer options in the RRMM setting




# Have A Question For the Presenters?

View right- hand side to submit a question




### Patients With Multiple Myeloma Are Living Longer Than Ever





## FDA-Approved Therapy for Multiple Myeloma Since 2000




CAR, chimeric antigen receptor; HDAC, histone deacetylase; MM, multiple myeloma; SINE, selective inhibitor of nuclear transport

Cancer.gov website. Drug therapy for multiple myeloma.

### Common Treatments for Multiple Myeloma<sup>1,2</sup>

#### Frontline (Induction)

- Rd: Lenalidomide/dex
- Vd: Bortezomib/dex
- **RVd lite:** Lenalidomide/bortezomib /dex lite
- VRd: Bortezomib/lenalidomide/dex
- KRd: Carfilzomib/lenalidomide/dex
- Dara Rd: Daratumumab/lenalidomide/dex
- Dara Cybord: Daratumumab/cyclophosphamide/ bortezomib/dex
- DaraVRD: Daratumumab/bortezomib/lenalid omide/dex



#### dex, dexamethasone; VTE, venous thromboembolism

1. Faiman B, et al. J Adv Pract Oncol. 2016:7(suppl 1):17-29; 2. NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma-v.4.2024.

### NCCN Recommendations for Adjunctive Treatment

#### Infection

- IVIG for recurrent infections
- Pneumococcal and influenza vaccine
- PJP, herpes and antifungal prophylaxis for high-dose or long-term steroids and teclistamab
- Herpes zoster prophylaxis with proteasome inhibitors, transplant, monoclonal antibodies, bispecific T-cell engagers

#### Bone disease

- Bisphosphonates, denosumab
- Radiation therapy
- Orthopedic consultation
- Vertebroplasty or kyphoplasty
- Calcium and Vitamin D supplementation

#### Renal dysfunction

- Avoid aggravating factors: contrast, NSAIDs, dehydration
- Not a contraindication to HCT
- Monitor bisphosphonates closely

#### Coagulation/thrombosis

- Prophylactic anticoagulation with IMiDs

#### Hypercalcemia

- Hydration, steroids, furosemide
- Zoledronic acid preferred
- Denosumab, calcitonin

#### Hyperviscosity

- Plasmapheresis

#### Anemia

- Consider erythropoietin
- Transfusion
- Type and screen patients prior to daratumumab administration




### Antigen Targets in Multiple Myeloma (MM)

#### BCMA<sup>1-3</sup>

Activates signal transduction pathways, upregulates anti-apoptotic proteins, and induces the expression of immunosuppressive molecules to drive MM cell proliferation and survival

#### GPRC5D<sup>4,5</sup>

G protein-coupled receptor family C group 5 member D (GPRC5D) primarily expressed on myeloma cells, and limited to the hair follicle of skin and hard keratinizing tissues



#### SLAMF7<sup>6</sup>

Highly expressed on MM cells Has a role in interactions between MM and stromal cells, as well as MM growth and survival and regulation of the immune response

#### **CD38**<sup>7,8</sup>


MM cells express high levels of CD38 Regulates migration and receptor-mediated adhesion and has ectoenzyme activity

#### SLAMF, signaling lymphocytic activation molecule family

1. D'Agostino M, et al. *Curr Hematol Malig Rep*. 2017;12(4):344-357; 2. Cho SF, et al. *Front Immunol*. 2018;9:1821; 3. Sanchez E, et al. *Br J Haematol*. 2012;158(6):727-738; 4. Mailankody S, et al. *N Engl J Med*. 2022;387:2296-1206; 5. Chari A, et al. *N Engl J Med*. 2022;387:2232-2244; 6. Tai YT, et al. *Blood*. 2008;112(4):1329-1337; 7. Malavasi F, et al. *Physiol Rev*. 2008;88:841-886; 8. Deaglio S, et al. *J Immunol*. 1998;160:395-402.




### Bispecifics vs Conventional Monoclonal Antibodies





### CAR T Cell and Bispecific Antibodies

#### Mechanism of Action<sup>1</sup>





1. Holstein SA, et al. J Clin Oncol. 2023;41(27):4416-4429. Epub 2023 Jul 20.

### FDA-approved T Cell-directed Therapies

#### Efficacy Data – Registrational Trials<sup>1-3</sup>

Therapy	N	Median Previous Lines of Therapy, No. (range)	Triple Class Refractory, %	Penta-Drug Refractory, %	High-Risk, %	ORR, %	≥CR, %	PFS	DOR	OS
Ide-cel <sup>8</sup>	128	6 (3-16)	84	26	35	73	33	Median 8.8 months	Median 10.7 months	Median 19.4 months
Cilta-cel9,16,17	97	6 (4-8)	88	42	24	98	82.5	Median 34.9 months	Median 33.9 months	63% at 3 years
Teclistamab <sup>10</sup>	165	5 (2-14)	78	30	26	63	39.4	Median 11.3 months	Median 18.4 months	Median 18.3 months
Talquetamab	232	6 (2-20)	75 SC 85 IV	25 SC 35 IV	16	63-72	21-28	Not reported	Median 7.8 - 10.2 months	Not reported
Elranatamab	123	5 (2-22)	100	87	25	61	35	Not reached at median follow up of 14.7 months	Not reached at median follow up of 14.7 months	Not reached at median follow up of 14.7 months


### The FDA has mandated a black box warning for all marketed CAR-T therapies, citing a potential risk of inducing malignant T-cell tumors.

CR, complete response; DOR, duration of response; ORR, overall response rate; OS, overall survival; PFS, progression-free survival

1. Holstein SA, et al. *J Clin Oncol*. 2023;41(27):4416-4429. Epub 2023 Jul 20; 2. Chari A, et al. *N Engl J Med*. 2022;387:2232-2244; 3. Lesokhin AM, et al. *Nat Med*. 2023;29(9):2259-2267.



### Overview of CAR T Cell Therapy





### Bridging Therapy Goals:

#### Disease Control and to Decrease Tumor Burden

#### Regimens

- Steroids (eg, dexamethasone)
- Previous treatment
- Selinoxor/pomalidomide /dexamethasone
- D-PACE or D-ACE
- Salvage auto transplant
- Radiation

#### Indications

- Control disease/rapidly
   growing disease
- Bulky disease
- Symptomatic patient (pain)
- Major organ involvement
   or obstruction
- Expected delay in CAR T cell production

#### **Regimen selection**

- Prior therapies
- Regimen-related
   AEs
- Site(s) of disease
- Comorbidities
- Blood counts
- Simplicity of administration



### Lymphodepletion

Lymphodepletion is necessary for expansion of CAR T cells:

- Lymphodepletion creates a "favorable" environment for CAR T cell expansion and survival *in vivo*
- Administered on D-5, D-4, D-3 before CAR T cells are infused on D + 0
  - Fludarabine 30 mg/m<sup>2</sup> IV daily and cyclophosphamide 300-500 mg/m<sup>2</sup> IV x 3 days.<sup>1-3</sup>



### Premedication and Prophylaxis Considerations<sup>1</sup>

Cell infusion premedication:

Acetaminophen and diphenhydramine (NO steroids)


Infection prophylaxis:

- Antiviral
- Antifungal and fluoroquinolone during neutropenic period
- PJP prophylaxis

Seizure prophylaxis may be considered



### CAR T Adverse Events and Timelines<sup>1,2</sup>





1. Brudno JN, et al. Blood. 2016;127:3321-3330; 2. Neelapu SS, et al. Nat Rev Clin Oncol. 2018; 15:47-62.

### CAR T-Cell AEs Onset

#### Acute AEs<sup>1</sup>

- Cytokine-release syndrome
- Immune effector cell—associated neurotoxicity syndrome
- Cytopenias
- Hemophagocytic lymphohistiocytosis/ macrophage activation syndrome

#### Delayed AEs<sup>2,3</sup>

- B-cell aplasia/hypogammaglobulinemia
- Prolonged cytopenias
- Late infections
- Long-term neurologic events/ movement and neurocognitive treatment-emergent AEs
- Transient cardiac AEs

#### Typically managed by CAR T Cell Center

### Typically managed by primary oncology team





**Cause:** Activation/expansion of CAR T cells

increases levels of cytokines

(IL-6, IL-15, INF-γ, GM-CSF, others)

**Onset:** variable; 1 to 5 days

Duration: 3 to 5 days

**Risk:** Variable up to 5% in >/= grade 3

- Disease burden
- Peak CAR T cell levels
- Pre-treatment and peak cytokine levels

#### **Biochemical Findings:**

- Organ-specific markers
  - Creatinine, blood urea nitrogen
  - Troponin
  - Aminotransferases (AST/ALT), bilirubin
- Cytokine panels not readily available for "real-time" clinical use
- Easy to measure surrogates: ferritin, C-reactive protein
  - Trend to monitor the tempo of CRS

In the end, CRS is a clinical, rather than laboratory diagnosis Cytokine levels do not influence grading or treatment



### Treatment of CRS: Tocilizumab

Description	Humanized anti-IL-6 receptor $IgG1_{K}$ monoclonal antibody			
Mechanism of action	Inhibits IL-6 mediated signaling by binding to both soluble and membrane-bound human IL-6 receptors			
FDA Expanded Approval 8/30/17	For the treatment of CAR T cell-induced severe or life-threatening CRS in patients 2 years of age and older			
Dose	<ul> <li>Adults: 8 mg/kg once (max dose of 800 mg)</li> <li>As frequent as every 8 hours, max of 4 doses total</li> </ul>			
Administration	Intravenous over 1 hour			
Required doses	Ensure that 2 doses of tocilizumab are available prior to infusion of CAR T cells			
Monitor	<ul> <li>For 7 days at the certified healthcare facility following infusion for signs and symptoms of CRS</li> <li>Monitor patients for signs or symptoms of CRS for 4 weeks after infusion and seek immediate medicate attention</li> </ul>			

CAR, chimeric antigen receptor





### Neurotoxicity Associated with CAR T Therapy<sup>1-4</sup>

#### Cause: Mechanism of toxicity is not clear

- T cell vs cytokine mediated??
- CAR T cells are seen in the CSF

Onset: 5-7 days after infusion; later than CRS

#### Duration: 5-10 days

• Fully reversible except in cases of fatal cerebral edema

#### Risk:

- High disease burden
- High IL-6 on Day 1
- Pre-treatment and peak cytokine levels
- Early or high-grade CRS
- Peak CAR T-cell levels

#### Neuro assessments

Wide range of symptoms from headache to encephalopathy, seizures

- Decreased attentiveness, anxiety, tremors, somnolence, disorientation, aphasia, nonsensical/tangential speech
- Parkinson-like movement disorders

#### Treatment:

- No clear response to anti-cytokine therapy
- Use of steroids and anti-seizure medications

CAR, chimeric antigen receptor; CRS, cytokine release syndrome; CSF, cerebrospinal fluid; DIC, disseminated intravascular coagulation

1. Maude SL, et al. *N Engl J Med*. 2014;371(16):1507-1517; 2. Davila ML, et al. *Sci Transl Med*. 2014;6(224):224ra25; 3. Lee DW, et al. *Lancet*. 2015;385(9967):517-528; 4. Kochendorfer JN, et al. *J Clin Oncol*. 2015;33(6):540-549.



### Medications Can Reduce Infection Risk

Type of Infection Risk	Medication Recommendation(s) for Healthcare Team Consideration <sup>1</sup>
Viral: HSV/VZV	Acyclovir prophylaxis
Bacterial: blood, pneumonia, and urinary tract infection	Consider prophylaxis with levofloxacin
PJP (P. jirovecii pneumonia)	Consider prophylaxis with trimethoprim-sulfamethoxazole
Fungal infections	Consider prophylaxis with fluconazole
COVID-19 and Influenza	Antiviral therapy if exposed or positive for covid per institution recommendations
IgG < 400 mg/dL (general infection risk)	Consider IVIg
ANC < 1000 cells/μL (general infection risk)	Consider GCSF 2 or 3 times/wk (or as frequently as needed) to maintain ANC > 1000 cells/ $\mu$ L and maintain treatment dose intensity

### Some people receiving BCMA-targeting therapies have experienced infections that are less common like CMV, PJP, EBV and fungal infections

ANC, absolute neutrophil count; CMV, cytomegalovirus; EBV, Epstein-Barr virus; GCSF, granulocyte colony-stimulating factor; HSV, herpes simplex virus; VZV, varicella zoster virus. 1. Raje NS, et al. *Lancet Haematol*.2022;9(2):143–161.



### **Bispecific Treatment Timeline**



Week 1: Step-up dosing to mitigate incidence and severity of CRS and neurotoxicity

- Allow 48 hours between doses to assess for emerging CRS or ICANS
- Observation recommended as inpatient during step-up dosing at a REMS certified facility
- Hold dose for evidence of CRS or ICANS or active infection
- Premedicate 1-3 hours prior to all step-up doses and first full dose, or if prior dose was associated with CRS or ICANS
- Recommended pre-medications: glucocorticoid steroid, antihistamine, and antipyretic
- Week 2 and onward: requires coordination of care with the community team and facility



### Teclistamab Safety

	Any Grade	Grade 3 or 4	
	no. of patients (%)	no. of patients (%)	
Neutropenia	118 (71.5)	108 (65.5)	
Anemia	90 (54.5)	62 (37.6)	
Thrombocytopenia	70 (42.4)	37 (22.4)	
Infections	132 (80.0)	91 (55.2)	
Cytokine release syndrome	119 (72.1)	1 (0.6)	
Diarrhea	56 (33.9)	6 (3.6)	
COVID-19	48 (29.1)	35 (21.2)	
ICANS	5 (3.03)	0	



### Teclistamab: CRS and ICANS Prevention and Management

- Step-up dosing: 0.06 mg/kg, 0.3 mg/kg, 1.5 mg/kg separated by at least 48 hours
- Hospitalization recommended but may not be essential with robust outpatient monitoring
- Dexamethasone (16 mg), acetaminophen, and diphenhydramine pre-medication before step-up and first full dose.
- Tocilizumab is preferred for CRS management, although tocilizumab is not mentioned in teclistamab's FDA prescribing information or REMS
- Dexamethasone is preferred for ICANS management



### Infections and Hypogammaglobulinemia

- Teclistamab phase 2 (N = 165)<sup>1,2</sup>
  - 80% developed infections, 55.2% grade 3-4
  - 74.5% developed hypogammaglobulinemia (IgG <500 mg/dL)
  - 12 deaths from COVID-19
  - 8 additional deaths from infections including one PML (JC virus)
  - 6 cases of pneumocystis pneumonia
- Talquetamab phase 2 (N = 232)<sup>3</sup>
  - ~40% developed infections, 7% grade 3-4
  - ~80% developed hypogammaglobulinemia
  - 1 fatal infection, and no COVID-19 deaths

\*\*Understanding of infection risk evolved during these studies, and many patients did not receive prophylaxis\*\*

IgG, immunoglobulin G; JC, human polyomavirus 2; PML, progressive multifocal leukoencephalopathy.



### Infection Prophylaxis With Bispecifics \*

- Herpes zoster prophylaxis (FDA prescribing information)<sup>1</sup>
- Intravenous immune globulin
- Pneumocystis prophylaxis for teclistamab
- Evaluate for CMV reactivation with cytopenias or other suggestive clinical symptoms
- Consider reduction in frequency to Q2W after stable response is achieved<sup>2</sup>

\* Will probably be the same for all anti-BCMA bispecific agents



### Management of Oral AEs<sup>1</sup>

**Taste Changes** 

Dexamethasone oral solutions "swish and spit" have been tried but with no proven benefit yet. Sour citrus or candies before meals are also recommended.

Glossitis and Thrush EARLY initiation of nystatin or mycelex is key to manage symptoms.

#### Dry Mouth

OTC dry mouth rinse, gel, spray are recommended. Consider saliva substitute. Advise patients to avoid hot beverages.

Dysphagia

Dietary modifications with small bites, eating upright, and sips with food can help manage symptoms.

- Weight loss and anorexia are associated with taste changes. Nutritionist involvement and dietary modifications are recommended to support patients. An appetite stimulant with Marinol, if indicated, can also be utilized.
- Education and emotional support are key strategies to manage oral toxicities.



1. Catamero D, Purcell K, Ray C, et al. Presented at the 20th International Myeloma Society (IMS) Annual Meeting Nurse Symposium; September 27–30, 2023; Athens, Greece.

OTC, over-the-counter

### Management of Dermatological AEs<sup>1</sup>

Dry Skin	Heavy moisturizers	Pruritus Loratadine 10 mg PO daily for 3–5 days post talquetamab				
Hand and/or foot peeling	Ammonium lactate 12% lotion to soles and palms BID	Injection site reaction				
Nail thinning and peeling	Nail hardeners, topical vitamin E oil, and triamcinolone 0.025% ointment	Body rash/ drug rash Above plus consider methylprednisolone taper and betamethasone 0.05% cream BID				
	<ul> <li>Consider dose HOLD for other grade 3 dermatologic AEs</li> <li>Dermatology consults may be helpful as an early strategy</li> </ul>					

- With experience, dermatologic AEs can be managed more easily vs oral AEs
- These interventions were successful at reducing or resolving dermatologic AEs

### Nail Changes (Associated with Talquetamab – GPRC5D)









Courtesy of Donna Catamaro, CRNP

### Palmar Plantar Desquamation (Associated with Talquetamab – GPRC5D)









### Comparison of Immunotherapy Approaches

	MoABs	CARs	BiTEs
Off-the-shelf	YES	No	Yes
Ease of administration	+++	+	+ to ++
Repeated dosing required	Yes	No	Yes
Dependent on patient T cell "fitness"	No	Yes	Yes
Adverse events	IRR	CRS, neuro	CRS, neuro
Adverse event duration	NA	~14-21 days	Ongoing
Durable clinical activity seen	Yes	Yes	Yes
Requires LD chemotherapy	NO	Yes	No

LD, lymphodepleting; IRR, infusion-related reaction; MoAB, monoclonal antibody



### Conclusion

- Significant advances in the treatment of myeloma continue to improve survival
- Highly effective immunotherapies, including CAR T and bispecifics, recently FDA approved for RRMM are showing great promise and are now moving earlier in lines of therapy at relapse.
- Close monitoring and aggressive management of the unique adverse events associated with these T cell-directed therapies is essential
- Adaption of these agents in RR disease is successfully moving to the community setting. Nurses, in community and CAR T centers, are essential in the successful coordination, symptom management and patient/family education.
- Myeloma patients are "Survivors"

